DOCSLIB.ORG

Functional Protein Tyrosine Phosphatases in Platelets A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

FUNCTIONAL PROTEIN TYROSINE PHOSPHATASES IN PLATELETS ________________________ A Dissertation Submitted to The Temple University Graduate Board ________________________ In Partial Fulfillment Of the Requirements for the Degree DOCTOR OF PHILOSOPHY ________________________ by Vaishali Vijay Inamdar December 2017 Dissertation Examining Committee: Dr. Satya P Kunapuli, Physiology Dr. Rosario Scalia, Physiology Dr. Laurie Kilpatrick, Physiology Dr. Xiongwen Chen, Physiology Dr. Ulhas Naik, Professor, Thomas Jefferson University ABSTRACT FUNCTIONAL PHOSPHATASES IN PLATELETS Platelets are small anucleate cells in blood that are derived from megakaryocytes and their primary function is to prevent bleeding. Upon vascular injury, the sub-endothelial collagen gets exposed to which platelets bind and aggregate eventually forming a platelet plug. There are several receptors on platelet surface that can be divided into two broad categories; the immune-receptor tyrosine-based activation motif (ITAM) and the G protein-coupled receptors (GPCRs). The role of several protein tyrosine kinases (PTKs) downstream of ITAM and GPCRs has been extensively studied. However, the role of protein tyrosine phosphatases (PTPs) have been under-investigated in platelets. PTPs are important for dephosphorylating and activating or inactivating the protein. Proteomics studies show presence of 10 receptor like and 10 cytoplasmic phosphatases in platelets. To date, only five non-transmembrane PTPs (NTPTPs), PTP-1B, Shp1, Shp2, LMW-PTP, MEG2-PTP and a one receptor- like PTP (RPTP), CD148, have been identified in platelets. Therefore, there is a need to explore the role of other PTPs in platelet activation. The main objective of this thesis was to determine the role of two PTPs – CD45 and PTPN7 in platelets. We first studied the role of CD45 in platelets. CD45 is a receptor protein tyrosine phosphatase present on the surface of all hematopoietic cells except for erythrocytes and platelets. Proteomics studies, however, have demonstrated the presence of a CD45 c- terminal catalytic peptide in platelets. Therefore, we investigated the functional role of ii this truncated isoform of CD45 in platelets, which contains the c-terminal catalytic domain but lacks the extracellular region. We used an antibody specific to the c-terminus of CD45 to confirm the presence of a truncated CD45 isoform in platelets. We also examined ex vivo and in vivo platelet function using CD45 KO mice. Aggregation and secretion mediated by the glycoprotein VI (GPVI) receptor was impaired in CD45 KO platelets. Consequently, CD45 KO mice had impaired hemostasis indicated by increased tail bleeding times. Also, using a model of pulmonary embolism we showed that CD45 KO mice had defective in vivo thrombus formation. Next, we investigated whether or not the truncated isoform of CD45 had a role in GPVI signaling. The full-length isoform of CD45 is known to regulate Src family kinase (SFK) activation in lymphocytes. We find a similar role for the truncated isoform of CD45 in platelets. SFK activation was impaired downstream of the GPVI receptor in the CD45 KO murine platelets. Consequently, Syk, and PLC2 activations were also impaired in CD45 KO murine platelets. Thus, we concluded that the truncated CD45 isoform regulates GPVI-mediated signaling and platelet functional responses by regulating SFK activation. Next, we investigated the role of another phosphatase PTPN7 in platelets. Thromboxane is a short-lived lipid mediator and acts as a local mediator to recruit more platelets to site of vascular injury and dysregulation of thromboxane generation can lead to several clinical complications like stroke, myocardial infarction etc. Extracellular signal- regulated protein kinase 1/2 (Erk1/2) plays an important role in promoting thromboxane generation in platelets. However, currently we have a poor understanding of how ERK is regulated in platelets. In lymphocytes ERK phosphorylation is regulated by a non- iii transmembrane protein tyrosine phosphatase PTPN7. Thus, we hypothesized that PTPN7 is present in platelets and it negatively regulates ERK activation and consequently thromboxane generation. We tested this hypothesis using a PTPN7 knockout mouse model. Using PTPN7 specific antibody for western blot analysis we demonstrated that PTPN7 is present in human as well as murine platelets. PTPN7 KO murine platelets show increased platelet functional responses such as aggregation, dense granule secretion and thromboxane generation upon stimulation with both GPCR and GPVI agonists. In presence of COX inhibitor indomethacin, the PTPN7 KO murine platelets aggregate and secrete to the same extent as the WT. This suggests that elevated thromboxane A2 levels are responsible for potentiation of platelet functional responses. ERK phosphorylation is also potentiated in PTPN7 KO and the activity of signaling molecules upstream of ERK such as MEK and PKC which are upstream of is unaffected. This shows that specificity of the PTPN7 towards ERK in platelets. Lastly, using the pulmonary embolism model we demonstrate a role for PTPN7 in thrombosis. Thus, we concluded that the PTPN7 regulates ERK activation and thromboxane generation in platelets. In conclusion, we demonstrated that truncated CD45 is a positive regulator of GPVI- mediated SFK activation and platelet functional responses and PTPN7 negatively regulates ERK phosphorylation and thromboxane generation in platelets. iv DEDICATION This dissertation is dedicated to my nephew Samved. v ACKNOWLEDGEMENT I would like to first of thank my mentor, Dr. Kunapuli, for giving me the opportunity to be a part of his lab and engage in platelet research for the last five years. Dr. Kunapuli is an excellent mentor and his teachings are invaluable. He has taught me how to systematically approach a problem, think critically and work efficiently and therefore has been a catalyst for my scientific career. I would like to acknowledge my committee members: Dr. Rosario Scalia, Dr. Laurie Kilpatrick, and Dr. Xiongwen Chen. I greatly appreciate all of their support, comments, and feedback during committee meetings. I would like to thank Dr. Laurie Kilpatrick for the guidance she provided while writing my outside research proposal for Ph.D. candidacy exam. I thank Dr. Ulhas Naik for his valuable inputs about my projects during Gordon research conference. I would like to thank Carol Dangelmaier for teaching me all the techniques in the lab and also helping me systematically troubleshoot. She has played a pivotal role in my understanding of techniques. I thank John Kostyak for helping me with all my projects and giving valuable advice and pep talks. All the current and former members of Dr. Kunapuli’s laboratory have been very supportive. I was fortunate to share my journey in Kunapuli lab with Rachit Badolia and Akruti Patel, they have truly made the Ph.D. journey more enjoyable. I would like to thank my seniors Dheeraj Bhavanasi and Bhanukanth Manne for their help with vi understanding the field. I would also like to thank Priyanka and Andrew for the initial support. I would like to thank Anushka Dixit who has been with me through thick and thin. My parents Vijay and Smita, sister Pallavi and brother in law Sumeet, have been extremely supportive, incessantly encouraging and constantly inspiring me to give my best. I can’t thank them enough; I am here because of them. I would also like to mention my 6-month-old nephew Samved, who is my lucky charm. Last but not the least, I would be indebted forever to all the mice that I have sacrificed during my projects, if it was not for them I would have never been able to conduct my research and write this thesis. vii TABLE OF CONTENTS ABSTRACT ...................................................................................................................... ii DEDICATION.................................................................................................................. v ACKNOWLEDGEMENT .............................................................................................. vi LIST OF FIGURES ......................................................................................................... x CHAPTER 1 ..................................................................................................................... 1 1 INTRODUCTION.................................................................................................... 1 1.1 Platelet Physiology ........................................................................................... 1 1.1.1 Introduction to platelets. ................................................................................ 1 1.1.2 Platelet Genesis .............................................................................................. 1 1.1.3 Platelet Anatomy ............................................................................................ 2 1.1.4 Platelet function in Hemostasis ...................................................................... 5 1.1.5 Other functions of platelets. ........................................................................... 9 1.2 Platelet Receptors........................................................................................... 11 1.3 Protein Tyrosine Kinases and Protein Tyrosine Phosphatases ................. 18 1.4 Protein Tyrosine Phosphatases ..................................................................... 18 1.4.1 Classification of PTPs .................................................................................
Recommended publications
  • The Expression Patterns and the Prognostic Roles of PTPN Family Members in Digestive Tract Cancers

    The Expression Patterns and the Prognostic Roles of PTPN Family Members in Digestive Tract Cancers

    Preprint: Please note that this article has not completed peer review. The expression patterns and the prognostic roles of PTPN family members in digestive tract cancers CURRENT STATUS: UNDER REVIEW Jing Chen The First Affiliated Hospital of China Medical University Xu Zhao Liaoning Vocational College of Medicine Yuan Yuan The First Affiliated Hospital of China Medical University Jing-jing Jing The First Affiliated Hospital of China Medical University [email protected] Author ORCiD: https://orcid.org/0000-0002-9807-8089 DOI: 10.21203/rs.3.rs-19689/v1 SUBJECT AREAS Cancer Biology KEYWORDS PTPN family members, digestive tract cancers, expression, prognosis, clinical features 1 Abstract Background Non-receptor protein tyrosine phosphatases (PTPNs) are a set of enzymes involved in the tyrosyl phosphorylation. The present study intended to clarify the associations between the expression patterns of PTPN family members and the prognosis of digestive tract cancers. Method Expression profiling of PTPN family genes in digestive tract cancers were analyzed through ONCOMINE and UALCAN. Gene ontology enrichment analysis was conducted using the DAVID database. The gene–gene interaction network was performed by GeneMANIA and the protein–protein interaction (PPI) network was built using STRING portal couple with Cytoscape. Data from The Cancer Genome Atlas (TCGA) were downloaded for validation and to explore the relationship of the PTPN expression with clinicopathological parameters and survival of digestive tract cancers. Results Most PTPN family members were associated with digestive tract cancers according to Oncomine, Ualcan and TCGA data. For esophageal carcinoma (ESCA), expression of PTPN1, PTPN4 and PTPN12 were upregulated; expression of PTPN20 was associated with poor prognosis.
  • Molecular Programming of Tumor-Infiltrating CD8 T Cells and IL15 Resistance

    Molecular Programming of Tumor-Infiltrating CD8 T Cells and IL15 Resistance

    Published OnlineFirst August 2, 2016; DOI: 10.1158/2326-6066.CIR-15-0178 Research Article Cancer Immunology Research Molecular Programming of Tumor-Infiltrating CD8þ T Cells and IL15 Resistance Andrew L. Doedens1, Mark P. Rubinstein1,2, Emilie T. Gross3, J. Adam Best1, David H. Craig2, Megan K. Baker2, David J. Cole2, Jack D. Bui3, and Ananda W. Goldrath1 Abstract Despite clinical potential and recent advances, durable immu- in the lung and spleen were activated and dramatically expanded. þ notherapeutic ablation of solid tumors is not routinely achieved. Tumor-infiltrating CD8 T cells exhibited cell-extrinsic and cell- IL15expandsnaturalkillercell(NK),naturalkillerTcell(NKT)and intrinsic resistance to IL15. Our data showed that in the case of þ CD8 T-cell numbers and engages the cytotoxic program, and thus persistent viral or tumor antigen, single-agent systemic IL15cx is under evaluation for potentiation of cancer immunotherapy. We treatment primarily expanded antigen-irrelevant or extratumoral þ found that short-term therapy with IL15 bound to soluble IL15 CD8 Tcells.Weidentified exhaustion, tissue-resident memory, þ receptor a–Fc (IL15cx; a form of IL15 with increased half-life and and tumor-specific molecules expressed in tumor-infiltrating CD8 activity) was ineffective in the treatment of autochthonous PyMT T cells, which may allow therapeutic targeting or programming þ murine mammary tumors, despite abundant CD8 T-cell infiltra- of specific subsets to evade loss of function and cytokine resist- tion. Probing of this poor responsiveness revealed that IL15cx ance, and, in turn, increase the efficacy of IL2/15 adjuvant cytokine þ only weakly activated intratumoral CD8 T cells, even though cells therapy.
  • Live-Cell Imaging Rnai Screen Identifies PP2A–B55α and Importin-Β1 As Key Mitotic Exit Regulators in Human Cells

    Live-Cell Imaging Rnai Screen Identifies PP2A–B55α and Importin-Β1 As Key Mitotic Exit Regulators in Human Cells

    LETTERS Live-cell imaging RNAi screen identifies PP2A–B55α and importin-β1 as key mitotic exit regulators in human cells Michael H. A. Schmitz1,2,3, Michael Held1,2, Veerle Janssens4, James R. A. Hutchins5, Otto Hudecz6, Elitsa Ivanova4, Jozef Goris4, Laura Trinkle-Mulcahy7, Angus I. Lamond8, Ina Poser9, Anthony A. Hyman9, Karl Mechtler5,6, Jan-Michael Peters5 and Daniel W. Gerlich1,2,10 When vertebrate cells exit mitosis various cellular structures can contribute to Cdk1 substrate dephosphorylation during vertebrate are re-organized to build functional interphase cells1. This mitotic exit, whereas Ca2+-triggered mitotic exit in cytostatic-factor- depends on Cdk1 (cyclin dependent kinase 1) inactivation arrested egg extracts depends on calcineurin12,13. Early genetic studies in and subsequent dephosphorylation of its substrates2–4. Drosophila melanogaster 14,15 and Aspergillus nidulans16 reported defects Members of the protein phosphatase 1 and 2A (PP1 and in late mitosis of PP1 and PP2A mutants. However, the assays used in PP2A) families can dephosphorylate Cdk1 substrates in these studies were not specific for mitotic exit because they scored pro- biochemical extracts during mitotic exit5,6, but how this relates metaphase arrest or anaphase chromosome bridges, which can result to postmitotic reassembly of interphase structures in intact from defects in early mitosis. cells is not known. Here, we use a live-cell imaging assay and Intracellular targeting of Ser/Thr phosphatase complexes to specific RNAi knockdown to screen a genome-wide library of protein substrates is mediated by a diverse range of regulatory and targeting phosphatases for mitotic exit functions in human cells. We subunits that associate with a small group of catalytic subunits3,4,17.
  • Phosphatases Page 1

    Phosphatases Page 1

    Phosphatases esiRNA ID Gene Name Gene Description Ensembl ID HU-05948-1 ACP1 acid phosphatase 1, soluble ENSG00000143727 HU-01870-1 ACP2 acid phosphatase 2, lysosomal ENSG00000134575 HU-05292-1 ACP5 acid phosphatase 5, tartrate resistant ENSG00000102575 HU-02655-1 ACP6 acid phosphatase 6, lysophosphatidic ENSG00000162836 HU-13465-1 ACPL2 acid phosphatase-like 2 ENSG00000155893 HU-06716-1 ACPP acid phosphatase, prostate ENSG00000014257 HU-15218-1 ACPT acid phosphatase, testicular ENSG00000142513 HU-09496-1 ACYP1 acylphosphatase 1, erythrocyte (common) type ENSG00000119640 HU-04746-1 ALPL alkaline phosphatase, liver ENSG00000162551 HU-14729-1 ALPP alkaline phosphatase, placental ENSG00000163283 HU-14729-1 ALPP alkaline phosphatase, placental ENSG00000163283 HU-14729-1 ALPPL2 alkaline phosphatase, placental-like 2 ENSG00000163286 HU-07767-1 BPGM 2,3-bisphosphoglycerate mutase ENSG00000172331 HU-06476-1 BPNT1 3'(2'), 5'-bisphosphate nucleotidase 1 ENSG00000162813 HU-09086-1 CANT1 calcium activated nucleotidase 1 ENSG00000171302 HU-03115-1 CCDC155 coiled-coil domain containing 155 ENSG00000161609 HU-09022-1 CDC14A CDC14 cell division cycle 14 homolog A (S. cerevisiae) ENSG00000079335 HU-11533-1 CDC14B CDC14 cell division cycle 14 homolog B (S. cerevisiae) ENSG00000081377 HU-06323-1 CDC25A cell division cycle 25 homolog A (S. pombe) ENSG00000164045 HU-07288-1 CDC25B cell division cycle 25 homolog B (S. pombe) ENSG00000101224 HU-06033-1 CDKN3 cyclin-dependent kinase inhibitor 3 ENSG00000100526 HU-02274-1 CTDSP1 CTD (carboxy-terminal domain,
  • Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response

    Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response

    DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response This information is current as Roland Lang, Michael Hammer and Jörg Mages of September 29, 2021. J Immunol 2006; 177:7497-7504; ; doi: 10.4049/jimmunol.177.11.7497 http://www.jimmunol.org/content/177/11/7497 Downloaded from References This article cites 82 articles, 53 of which you can access for free at: http://www.jimmunol.org/content/177/11/7497.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS DUSP Meet Immunology: Dual Specificity MAPK Phosphatases in Control of the Inflammatory Response1 Roland Lang,2 Michael Hammer, and Jo¨rg Mages The MAPK family members p38, JNK, and ERK are all promoters of e.g., Il6, Tnfa, and many other genes that are up- activated downstream of innate immunity’s TLR to in- regulated in response to TLR ligation.
  • Inhibition of Dual-Specificity Phosphatase 26 by Ethyl-3,4-Dephostatin: Ethyl-3,4-Dephostatin As a Multiphosphatase Inhibitor

    Inhibition of Dual-Specificity Phosphatase 26 by Ethyl-3,4-Dephostatin: Ethyl-3,4-Dephostatin As a Multiphosphatase Inhibitor

    ORIGINAL ARTICLES College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea Inhibition of dual-specificity phosphatase 26 by ethyl-3,4-dephostatin: Ethyl-3,4-dephostatin as a multiphosphatase inhibitor HUIYUN SEO, SAYEON CHO Received September 30, 2015, accepted November 6, 2015 Sayeon Cho, Ph.D., College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea [email protected] Pharmazie 71: 196–200 (2016) doi: 10.1691/ph.2016.5803 Protein tyrosine phosphatases (PTPs) regulate protein function by dephosphorylating phosphorylated proteins in many signaling cascades and some of them have been targets for drug development against many human diseases. There have been many reports that some chemical inhibitors could regulate particular phosphatases. However, there was no extensive study on specificity of inhibitors towardss phosphatases. We investigated the effects of ethyl-3,4-dephostatin, a potent inhibitor of five PTPs including PTP-1B and Src homology-2-containing protein tyrosine phosphatase-1 (SHP-1), on thirteen other PTPs using in vitro phosphatase assays. Of them, dual-specificity protein phosphatase 26 (DUSP26), which inhibits mitogen-activated protein kinase (MAPK) and p53 tumor suppressor and is known to be overexpressed in anaplastic thyroid carcinoma, was inhibited by ethyl- 3,4-dephostatin in a concentration-dependent manner. Kinetic studies with ethyl-3,4-dephostatin and DUSP26 revealed competitive inhibition, suggesting that ethyl-3,4-dephostatin binds to the catalytic site of DUSP26 like other substrate PTPs. Moreover, ethyl-3,4-dephostatin protects DUSP26-mediated dephosphorylation of p38, a member of the MAPK family, and p53. Taken together, these results suggest that ethyl-3,4-dephostatin functions as a multiphosphatase inhibitor and is useful as a therapeutic agent for cancers overexpressing DUSP26.
  • Protein Tyrosine Phosphatases in Health and Disease Wiljan J

    Protein Tyrosine Phosphatases in Health and Disease Wiljan J

    REVIEW ARTICLE Protein tyrosine phosphatases in health and disease Wiljan J. A. J. Hendriks1, Ari Elson2, Sheila Harroch3, Rafael Pulido4, Andrew Stoker5 and Jeroen den Hertog6,7 1 Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 2 Department of Molecular Genetics, The Weizmann Institute of Science, Rehovot, Israel 3 Department of Neuroscience, Institut Pasteur, Paris, France 4 Centro de Investigacio´ nPrı´ncipe Felipe, Valencia, Spain 5 Neural Development Unit, Institute of Child Health, University College London, UK 6 Hubrecht Institute, KNAW & University Medical Center Utrecht, The Netherlands 7 Institute of Biology Leiden, Leiden University, The Netherlands Keywords Protein tyrosine phosphatases (PTPs) represent a super-family of enzymes bone morphogenesis; hereditary disease; that play essential roles in normal development and physiology. In this neuronal development; post-translational review, we will discuss the PTPs that have a causative role in hereditary modification; protein tyrosine phosphatase; diseases in humans. In addition, recent progress in the development and synaptogenesis analysis of animal models expressing mutant PTPs will be presented. The Correspondence impact of PTP signaling on health and disease will be exemplified for the J. den Hertog, Hubrecht Institute, fields of bone development, synaptogenesis and central nervous system dis- Uppsalalaan 8, 3584 CT Utrecht, eases. Collectively, research on PTPs since the late 1980’s yielded the The Netherlands cogent view that development of PTP-directed
  • Complex Oncogene Dependence in Microrna-125A– Induced Myeloproliferative Neoplasms

    Complex Oncogene Dependence in Microrna-125A– Induced Myeloproliferative Neoplasms

    Complex oncogene dependence in microRNA-125a– induced myeloproliferative neoplasms Shangqin Guoa,b, Haitao Baib,c, Cynthia M. Megyolaa,b, Stephanie Halenea,d,e, Diane S. Krausea,e,f, David T. Scaddeng, and Jun Lua,b,e,1 bDepartment of Genetics, dDepartment of Medicine, fDepartment of Laboratory Medicine, aYale Stem Cell Center, and eYale Cancer Center, Yale University School of Medicine, New Haven, CT 06520; gCenter for Regenerative Medicine, Massachusetts General Hospital, Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Boston, MA 02114; and cDepartment of Hematology, Shanghai First People’s Hospital Shanghai 200080, China Edited by Sherman M. Weissman, Yale University, New Haven, CT, and approved August 30, 2012 (received for review August 2, 2012) Deregulation of microRNA (miRNA) expression can lead to cancer neoplasms, MPNs) are a collection of hematopoietic diseases initiation and progression. However, limited information exists on the with common features (reviewed in refs. 13 and 14), such as function of miRNAs in cancer maintenance. We examined these issues overproduction of one or more myeloid/erythroid/platelet line- in the case of myeloproliferative diseases and neoplasms (MPN), ages and splenomegaly. In some patients, the MPN will progress a collection of hematopoietic neoplasms regarded as preleukemic, to acute myeloid leukemia, leading to the notion that MPN is thereby representing early neoplastic states. We report here that one of the preleukemic states of a full-blown myeloid leukemia. microRNA-125a (miR-125a)–induced MPN display a complex manner In this study, we used genomics and genetics to explore the role of oncogene dependence. Following a gain-of-function genomics of miRNAs in MPN and the dependence of the early neoplastic screen, we overexpressed candidate miR-125a in vivo, which led MPN state on an oncogenic miRNA.
  • Mutations in the RAS-BRAF-MAPK-ERK Pathway

    Mutations in the RAS-BRAF-MAPK-ERK Pathway

    Chronic Lymphocytic Leukemia SUPPLEMENTARY APPENDIX Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia Neus Giménez, 1,2 * Alejandra Martínez-Trillos, 1,3 * Arnau Montraveta, 1 Mónica Lopez-Guerra, 1,4 Laia Rosich, 1 Ferran Nadeu, 1 Juan G. Valero, 1 Marta Aymerich, 1,4 Laura Magnano, 1,4 Maria Rozman, 1,4 Estella Matutes, 4 Julio Delgado, 1,3 Tycho Baumann, 1,3 Eva Gine, 1,3 Marcos González, 5 Miguel Alcoceba, 5 M. José Terol, 6 Blanca Navarro, 6 Enrique Colado, 7 Angel R. Payer, 7 Xose S. Puente, 8 Carlos López-Otín, 8 Armando Lopez-Guillermo, 1,3 Elias Campo, 1,4 Dolors Colomer 1,4 ** and Neus Villamor 1,4 ** 1Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona; 2Anaxomics Biotech, Barcelona; 3Hematol - ogy Department and 4Hematopathology Unit, Hospital Clinic, Barcelona; 5Hematology Department, University Hospital- IBSAL, and In - stitute of Molecular and Cellular Biology of Cancer, University of Salamanca, CIBERONC; 6Hematology Department, Hospital Clínico Universitario, Valencia: 7Hematology Department, Hospital Universitario Central de Asturias, Oviedo, and 8Departamento de Bio - química y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, CIBERONC, Spain. *NG and AM-T contributed equally to the study. **DC and NV share senior authorship of the manuscript. ©2019 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.196931 Received: May 1, 2018. Accepted: September 26, 2018. Pre-published: September 27, 2018. Correspondence: DOLORS COLOMER [email protected] Supplemental data METHODS Primary CLL cells Cells were isolated from peripheral blood (PB) samples by Ficoll-Paque sedimentation (GE-Healthcare, Chicago, IL, USA).

  • Identification of PTPN1 As a Novel Negative Regulator of the JNK MAPK

    www.nature.com/scientificreports OPEN Identifcation of PTPN1 as a novel negative regulator of the JNK MAPK pathway using a synthetic Received: 22 May 2017 Accepted: 25 September 2017 screening for pathway-specifc Published: xx xx xxxx phosphatases Jiyoung Moon , Jain Ha & Sang-Hyun Park The mitogen activated protein kinase (MAPK) signaling cascades transmit extracellular stimulations to generate various cellular responses via the sequential and reversible phosphorylation of kinases. Since the strength and duration of kinase phosphorylation within the pathway determine the cellular response, both kinases and phosphatases play an essential role in the precise control of MAPK pathway activation and attenuation. Thus, the identifcation of pathway-specifc phosphatases is critical for understanding the functional mechanisms by which the MAPK pathway is regulated. To identify phosphatases specifc to the c-Jun N-terminal kinase (JNK) MAPK pathway, a synthetic screening approach was utilized in which phosphatases were individually tethered to the JNK pathway specifc-JIP1 scafold protein. Of 77 mammalian phosphatases tested, PTPN1 led to the inhibition of JNK pathway activation. Further analyses revealed that of three pathway member kinases, PTPN1 directly dephosphorylates JNK, the terminal kinase of the pathway, and negatively regulates the JNK MAPK pathway. Specifcally, PTPN1 appears to regulate the overall signaling magnitude, rather than the adaptation timing, suggesting that PTPN1 might be involved in the control and maintenance of signaling noise. Finally, the negative regulation of the JNK MAPK pathway by PTPN1 was found to reduce the tumor necrosis factor α (TNFα)-dependent cell death response. Te mitogen-activated protein kinase (MAPK) pathways are evolutionally conserved among eukaryotes, and regulate diverse cellular responses, including cell proliferation, differentiation, and death1,2.
  • Research Article Gene Expression Profiles of Human Phosphotyrosine Phosphatases Consequent to Th1 Polarisation and Effector Function

    Research Article Gene Expression Profiles of Human Phosphotyrosine Phosphatases Consequent to Th1 Polarisation and Effector Function

    Hindawi Journal of Immunology Research Volume 2017, Article ID 8701042, 12 pages https://doi.org/10.1155/2017/8701042 Research Article Gene Expression Profiles of Human Phosphotyrosine Phosphatases Consequent to Th1 Polarisation and Effector Function Patricia Castro-Sánchez, Rocio Ramirez-Munoz, and Pedro Roda-Navarro Department of Microbiology I (Immunology), School of Medicine, Complutense University and “12 de Octubre” Health Research Institute, Madrid, Spain Correspondence should be addressed to Pedro Roda-Navarro; [email protected] Received 4 December 2016; Accepted 14 February 2017; Published 14 March 2017 Academic Editor: Andreia´ M. Cardoso Copyright © 2017 Patricia Castro-Sanchez´ et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Phosphotyrosine phosphatases (PTPs) constitute a complex family of enzymes that control the balance of intracellular phosphorylation levels to allow cell responses while avoiding the development of diseases. Despite the relevance of CD4 T cell polarisation and effector function in human autoimmune diseases, the expression profile of PTPs during T helper polarisation and restimulation at inflammatory sites has not been assessed. Here, a systematic analysis of the expression profile of PTPs hasbeen 2+ carried out during Th1-polarising conditions and upon PKC activation and intracellular raise of Ca in effector cells. Changes in gene expression levels suggest a previously nonnoted regulatory role of several PTPs in Th1 polarisation and effector function. A substantial change in the spatial compartmentalisation of ERK during T cell responses is proposed based on changes in the dose of cytoplasmic and nuclear MAPK phosphatases.
  • The Expression Patterns and the Diagnostic/Prognostic Roles of PTPN

    The Expression Patterns and the Diagnostic/Prognostic Roles of PTPN

    Chen et al. Cancer Cell Int (2020) 20:238 https://doi.org/10.1186/s12935-020-01315-7 Cancer Cell International PRIMARY RESEARCH Open Access The expression patterns and the diagnostic/ prognostic roles of PTPN family members in digestive tract cancers Jing Chen1,2,3, Xu Zhao4, Yuan Yuan1,2,3* and Jing‑Jing Jing1,2,3* Abstract Background: Non‑receptor protein tyrosine phosphatases (PTPNs) are a set of enzymes involved in the tyrosyl phos‑ phorylation. The present study intended to clarify the associations between the expression patterns of PTPN family members, and diagnosis as well as the prognosis of digestive tract cancers. Methods: Oncomine and Ualcan were used to analyze PTPN expressions. Data from The Cancer Genome Atlas (TCGA) were downloaded through UCSC Xena for validation and to explore the relationship of the PTPN expression with diagnosis, clinicopathological parameters and survival of digestive tract cancers. Gene ontology enrichment analysis was conducted using the DAVID database. The gene–gene interaction network was performed by GeneMA‑ NIA and the protein–protein interaction (PPI) network was built using STRING portal coupled with Cytoscape. The expression of diferentially expressed PTPNs in cancer cell lines were explored using CCLE. Moreover, by histological verifcation, the expression of four PTPNs in digestive tract cancers were further analyzed. Results: Most PTPN family members were associated with digestive tract cancers according to Oncomine, Ualcan and TCGA data. Several PTPN members were diferentially expressed